ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda and Qilu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaQilu Pharmaceutical
studies on the registry1,754218
open to participants now86135
phase 3 studies under way4453
reach primary completion within a year4749
programswith a study of their own in two years2571

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaQilu Pharmaceutical
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%

Qilu Pharmaceutical: 23 of its 71 programs at phase 1

  1. apripitant and palonosetron injectable emulsionphase 1
  2. follitropin alfaphase 1
  3. Meropenem-Pralubactamphase 1
  4. QL2302phase 1
  5. QLF4113phase 1

and 18 more — sign in to see them all

32%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Qilu Pharmaceutical: 14 of its 71 programs at phase 2

  1. QLS1410phase 2
  2. QLS12010phase 2
  3. KRAS G12D Inhibitor QLC1101phase 2
  4. QLH12016phase 2
  5. QLC1401phase 2

and 9 more — sign in to see them all

20%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Qilu Pharmaceutical: 32 of its 71 programs at phase 3

  1. Iparomlimab/Tuvonralimabphase 3
  2. QLC5508phase 3
  3. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3
  4. QL2107phase 3
  5. QLC7401phase 3

and 27 more — sign in to see them all

45%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Qilu Pharmaceutical: 2 of its 71 programs at approved, new studies

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study
  2. Tafamidis Meglumine Soft Capsulesapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Qilu Pharmaceutical36 readouts · 13 phase 3

Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion

  1. apripitant and palonosetron injectable emulsionphase 1 · Nov 0 · NCT07817004
  2. QLS1304phase 2 · Nov 0 · NCT06823609

Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3 · Dec 0 · NCT06942767
  2. pralurbactamphase 3 · Dec 0 · NCT07089186
  3. QL1207Hphase 3 · Dec 0 · NCT07489586
  4. QL2107phase 3 · Dec 0 · NCT06754644
  5. QLG1091phase 3 · Dec 0 · NCT07487103

and 4 more — sign in to see them all

Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QL1206phase 3 · Jan 0 · NCT07062978
  2. QLS1510phase 1 · Jan 30 · NCT07760077

Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. QLC1401phase 2 · Feb 0 · NCT07173556

Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLH2405phase 1 · Mar 0 · NCT07489599
  2. QLM3003phase 3 · Mar 0 · NCT06880276

Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-HER2 Monoclonal Antibody QL1209phase 3 · Apr 0 · NCT07861139
  2. Platinum Compoundsphase 2 · Apr 0 · NCT07453394
  3. QLS1209phase 1 · Apr 0 · NCT06872580
  4. QLS5132phase 3 · Apr 0 · NCT07453394
  5. QL0911phase 3 · Apr 30 · NCT06456528

Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-B7-H3 Antibody-drug Conjugate MHB088Cphase 3 · May 0 · NCT06954246
  2. daprodustatphase 3 · May 0 · NCT07300111
  3. QL2108phase 3 · May 0 · NCT06884891
  4. QLG2128phase 3 · May 0 · NCT06898060

Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3 · Jun 0 · NCT06732323
  2. Iparomlimab/Tuvonralimabphase 3 · Jun 0 · NCT07272590
  3. QL2401phase 2 · Jun 0 · NCT07620366
  4. QLC5513phase 2 · Jun 0 · NCT07272590
  5. QLS5308phase 1 · Jun 0 · NCT07462442

and 2 more — sign in to see them all

Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion

  1. QLS5133phase 2 · Jul 0 · NCT07061639

Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion

  1. QLS2406-1 injectionphase 1 · Aug 30 · NCT07937787
·

Qilu Pharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLC7401phase 3 · Oct 7 · NCT07444086
  2. QLS2312phase 1 · Oct 9 · NCT07861581
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Qilu Pharmaceutical

New programs 6

Reached a new phase 2

  • QLS4131phase 3 · Nov 6 · Multiple Myeloma
  • QLS5132phase 3 · Oct 20 · Carcinoma, Ovarian Epithelial

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 16 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionTakedaQilu Pharmaceutical
Prostatic Neoplasmsboth · compare here

Takeda in Prostatic Neoplasms: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Prostatic Neoplasms in search

Qilu Pharmaceutical in Prostatic Neoplasms: 5 programs

  1. QLC5508phase 3
  2. QLG1080phase 3
  3. QLH12016phase 2
  4. QLF4113phase 1
  5. QLS2401phase 1

Their studies: Qilu Pharmaceutical’s studies of Prostatic Neoplasms in search

Multiple Myelomaboth · compare here

Takeda in Multiple Myeloma: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Multiple Myeloma in search

Qilu Pharmaceutical in Multiple Myeloma: 4 programs

  1. QL2109phase 3
  2. QLS4131phase 3
  3. QLS32015phase 3
  4. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Multiple Myeloma in search

Lupus Erythematosus, Systemicboth · compare here

Takeda in Lupus Erythematosus, Systemic: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Lupus Erythematosus, Systemic in search

Qilu Pharmaceutical in Lupus Erythematosus, Systemic: 3 programs

  1. QLS4131phase 3
  2. QLS2404phase 1
  3. QLS2416phase 1

Their studies: Qilu Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Qilu Pharmaceutical in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. QL0911phase 3
  2. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Alzheimer Diseaseboth · compare here

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Qilu Pharmaceutical in Alzheimer Disease: 1 program

  1. QLH2405phase 1

Their studies: Qilu Pharmaceutical’s studies of Alzheimer Disease in search

Carcinoma, Renal Cellboth · compare here

Takeda in Carcinoma, Renal Cell: 1 program

  1. Vinblastineapproved, new study

Their studies: Takeda’s studies of Carcinoma, Renal Cell in search

Qilu Pharmaceutical in Carcinoma, Renal Cell: 1 program

  1. QLS5133phase 2

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Renal Cell in search

Depressive Disorder, Majorboth · compare here

Takeda in Depressive Disorder, Major: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depressive Disorder, Major in search

Qilu Pharmaceutical in Depressive Disorder, Major: 1 program

  1. Aprepitantphase 3

Their studies: Qilu Pharmaceutical’s studies of Depressive Disorder, Major in search

Fatty Liverboth · compare here

Takeda in Fatty Liver: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Fatty Liver in search

Qilu Pharmaceutical in Fatty Liver: 1 program

  1. QL2401phase 2

Their studies: Qilu Pharmaceutical’s studies of Fatty Liver in search

Hidradenitis Suppurativaboth · compare here

Takeda in Hidradenitis Suppurativa: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Hidradenitis Suppurativa in search

Qilu Pharmaceutical in Hidradenitis Suppurativa: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Hidradenitis Suppurativa in search

Ischemic Strokeboth · compare here

Takeda in Ischemic Stroke: 1 program

  1. apadamtase alfaphase 3

Their studies: Takeda’s studies of Ischemic Stroke in search

Qilu Pharmaceutical in Ischemic Stroke: 1 program

  1. Monosialogangliosidephase 3

Their studies: Qilu Pharmaceutical’s studies of Ischemic Stroke in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Takeda in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. Brentuximab Vedotinapproved, new study

Their studies: Takeda’s studies of Lymphoma, Large B-Cell, Diffuse in search

Qilu Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Myelodysplastic Syndromesboth · compare here

Takeda in Myelodysplastic Syndromes: 1 program

  1. elriterceptphase 3

Their studies: Takeda’s studies of Myelodysplastic Syndromes in search

Qilu Pharmaceutical in Myelodysplastic Syndromes: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Myelodysplastic Syndromes in search

Show all 16

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Qilu Pharmaceutical 18 of 71 programs (30 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.